The FDA verdict on Elagolix, an investigational treatment for the management of endometriosis with associated pain, is scheduled to be announced in Q2 2018.Endometriosis occurs when bits of the tissue that lines the uterus (endometrium) grow on other pelvic organs, such as the ovaries or fallopian tubes. Outside the uterus, endometrial tissue thickens and bleeds, just as the normal endometrium does during the menstrual cycle. (Source: Mayo Clinic) Elagolix, formerly known as ABT-620, is an oral gonadotropin-releasing hormone antagonist being co-developed by AbbVie (ABBV) and Neurocrine Biosciences (NBIX).If approved, Elagolix will be the first new oral medical management treatment option for endometriosis-associated pain in more than a decade.Elagolix is also being explored in the treatment of uterine fibroids.Analysts expect the drug to become a blockbuster.ABBV closed Tuesday’s (Mar.27) trading at $92.01, down 3.43%.